The Neurology Minute® podcast delivers a brief daily summary of what you need to know in the field of neurology, the latest science focused on the brain, and timely topics explored by leading neurologists and neuroscientists. From the American Academy of Neurology and hosted by Stacey Clardy, MD, PhD, FAAN, with contributions by experts from the Neurology® journals, Neurology Today®, Continuum®, and more.
An AAN advocacy update describes BrainPAC’s candidate scorecard and opposition to proposed hospital outpatient botulinum toxin prior authorisation and a separate 50% same-day service payment reduction, while distinguishing both proposals from implemented policy.
Newer myasthenia gravis treatments show comparable reductions in QMG and MgAdL scores in the reported network meta-analysis, leaving administration, cost, treatment response and patient preferences important when clinicians and patients choose between available options.
The HARVEST trial finds no survival benefit from rifampicin 35 mg/kg compared with 10 mg/kg in tuberculous meningitis, with possible harm; increased dexamethasone metabolism offers one proposed mechanism and supports retaining standard rifampicin dosing.
Safer clinical artificial intelligence use depends on recognising incorrect outputs, potential reuse of sensitive information and environmental costs; training should address these risks while acknowledging that electronic records, workflows and patient encounters differ across healthcare systems.
Artificial intelligence may assist neurological diagnosis, including in emergency care, but remains a clinical tool rather than a replacement for history-taking or neurological examination, with training relevant to senior neurologists and consultants as well as residents.
Accessible brain health education combines trusted expert information, practical resources and personal stories to help patients, families and communities understand complex subjects, share what they learn and identify useful next steps throughout life.
Early dexamethasone alongside antibiotics in pneumococcal meningitis aims to limit the inflammatory response to infection and bacterial killing, with benefits for hearing and cognition dependent on giving treatment before or soon after the first antibiotic dose.
Prospective Dutch cohort data associate early, complete dexamethasone treatment with better outcomes in Listeria meningitis, challenging older advice to stop steroids once Listeria is identified while leaving important uncertainty because the evidence is observational rather than randomised.
Newer myasthenia gravis treatments including FCR inhibitors, complement inhibitors and CD19 plus B-cell depletion therapy show comparable efficacy and similar adverse-effect findings in a Bayesian meta-analysis, but differences between trial populations limit confident treatment ranking.
Adjunctive dexamethasone in herpes simplex virus encephalitis did not improve verbal memory or neurological outcomes in the main DEX-ENCEPH analysis, although an exploratory timing analysis suggested possible benefit from very early treatment without evidence of impaired viral clearance.
.svg)